RecruitingNot ApplicableNCT07244029

Aescin-Based Herbal Extract (Reparil) for Postoperative Sequelae After Mandibular Third Molar Surgery

Evaluation of Aescin-Based Herbal Extracts for Managing Postoperative Sequelae Following Impacted Mandibular Third Molar Surgery: A Randomized, Single-Blind, Controlled Trial

Sponsor

Oman Medical Speciality Board

Enrollment

100 participants

Start Date

Jan 1, 2026

Study Type

INTERVENTIONAL

Conditions

Postoperative Pain Trismus Facial Swelling

Summary

This randomized, single-blind, controlled clinical trial aims to evaluate the efficacy and safety of Aescin-based herbal extract (Reparil®) compared with Ibuprofen in managing postoperative sequelae following surgical removal of impacted mandibular third molars. A total of 100 participants aged 18-40 years will be enrolled at the Dental Center, Medical City Hospital for Military and Security Services (MCMSS), Al Khoud, Oman. Participants will be randomly assigned to receive either Reparil® (Aescin 20 mg, three times daily for five days) or Ibuprofen (400 mg, three times daily for five days) following standardized third molar extraction procedures. Postoperative outcomes including pain (VAS), facial swelling (3D facial scanner), and mouth opening (digital caliper) will be assessed preoperatively, on day 2, and day 7 post-surgery. The study aims to determine whether Aescin offers comparable analgesic and anti-edematous effects to Ibuprofen with fewer adverse events.

Eligibility

Min Age: 18 YearsMax Age: 40 Years

Inclusion Criteria5

Patients indicated for surgical removal of impacted mandibular third molars according to National Institute for Health and Care Excellence (NICE) guidelines.
Age between 18 and 40 years.
Impacted mandibular third molars with similar anatomical position and difficulty level as classified by Pell and Gregory and Pederson scoring.
Healthy individuals (ASA I-II) with no significant systemic illness.
Willing to provide written informed consent and attend all follow-up visits (Day 2 and Day 7 post-surgery).

Exclusion Criteria6

Recent use (within three weeks preoperatively) of anti-inflammatories, corticosteroids, or antibiotics.
Known allergies or hypersensitivity to Aescin, Ibuprofen, rescue medications, or local anesthetics.
Pregnant or lactating women.
Patients with contraindications to NSAIDs (e.g., asthma, bleeding disorders, chronic kidney disease, active peptic ulcer, or cardiovascular disease).
Recent use of substances that may affect surgery or interact with study drugs (e.g., contraceptives, alcohol, or tobacco).
Surgical time exceeding 30 minutes or cases with intraoperative complications requiring non-study medications.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEscin

Oral administration of Aescin 20 mg (Reparil®-Dragees, Meda Pharmaceuticals, Germany), taken three times daily (TID) for five consecutive days following surgical extraction of an impacted mandibular third molar. Each tablet contains 20 mg of purified Aescin derived from Aesculus hippocastanum.

DRUGIbuprofen 400 mg

Oral administration of Ibuprofen 400 mg tablets (Flamingo Pharmaceuticals Ltd., India), taken three times daily (TID) for five consecutive days following surgical extraction of an impacted mandibular third molar.